Filing Flows › Precigen (PGEN) › Q2 2026 › vs Q1 2026
Precigen (PGEN) Q2 2026 vs Q1 2026 (quarter over quarter)
Precigen's revenue rose $31.7M (+136%) from $23.3M in Q1 2026 to $55.0M in Q2 2026. The biggest changes: Product revenues, net +$31.4M (+144%); Service revenues +$292K (+21%); Exemplar −$45K (-19%). Operating margin 41.2% against -25.8% (+67.0 pts).
Precigen, Q2 2026: revenue $55.0M (64× year over year), operating margin 41.2%, net earnings $20.1M, operating cash flow −$17.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 41.2% | -25.8% | +67.0 pts |
| Net margin | 36.5% | -34.1% | +70.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product revenues, net | $53.3M | $21.8M | $31.4M | +144% |
| Service revenues | $1.7M | $1.4M | $292K | +21% |
| Exemplar | $192K | $237K | −$45K | -19% |
| Revenue | $55.0M | $23.3M | $31.7M | +136% |
| Operating profit | $22.6M | −$6.0M | $28.6M | — |
| Costs & expenses | $32.3M | $29.2M | $3.1M | +11% |
| Pre-tax earnings | $20.1M | −$7.9M | $28.0M | — |
| Other expense, net | $2.6M | $1.9M | $636K | +33% |
| Research & development | $7.3M | $5.6M | $1.6M | +29% |
| SG&A | $22.2M | $21.0M | $1.2M | +6% |
| Other operating costs | $2.8M | $2.6M | $246K | +10% |
| Net earnings | $20.1M | −$7.9M | $28.0M | — |
| Operating cash sources | $42.6M | $40.0M | $2.6M | +6% |
| Depreciation & amortization | $1.1M | $1.1M | $2K | +0.2% |
| Share-based compensation | $3.6M | $3.0M | $574K | +19% |
| Cash used in operations | $17.8M | $43.8M | −$26.0M | -59% |
| Working capital & other | $42.6M | $40.0M | $2.6M | +6% |
Questions
How much did Precigen's revenue grow quarter over quarter in Q2 2026?
Precigen's revenue rose $31.7M (+136%) from $23.3M in Q1 2026 to $55.0M in Q2 2026.
What drove Precigen's revenue change in Q2 2026?
Product revenues, net +$31.4M (+144%); Service revenues +$292K (+21%); Exemplar −$45K (-19%).